featured
mFOLFOXIRI With Cetuximab as Conversion Therapy in Patients With RAS/BRAF Wild-Type Unresectable Colorectal Liver Metastases
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Oncologist